In fact, the presence of constitutively active KRAS sensitizes cancer cells to MEK and BCL-XL [7] or RAF [8] inhibition, TRAIL [9], 5-FU and oxaliplatin [10]. The gene discussed is TNFSF10; the disease is cancer.